Pimasertib clinical trials
Also written MSC1936369B and AS703026.
Includes 2 studies of Pimasertib hydrochloride.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses pimasertib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2011 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 3 |
| 2013 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 1
EMD Serono (7) · Merck KGaA, Darmstadt, Germany (3) · Sanofi (1) · M.D. Anderson Cancer Center (1) · Day One Biopharmaceuticals, Inc. (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses pimasertib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 13
- Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain MetastasesTerminatedPhase 1/2M.D. Anderson Cancer CenterNCT04789668Written as Pimasertib
- Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid TumorsTerminatedPhase 1Day One Biopharmaceuticals, Inc.NCT07121829Written as Tovorafenib Drug: Pimasertib
- Trial of MSC1936369B in Subjects With Solid TumorsCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT00982865Written as MSC1936369B
- Combination Trial of Pimasertib (MSC1936369B) With TemsirolimusTerminatedPhase 1EMD SeronoNCT01378377Written as Pimasertib
- Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous MelanomaCompletedPhase 2EMD SeronoNCT01693068Written as Pimasertib
- A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as MonotherapyTerminatedPhase 1Merck KGaA, Darmstadt, GermanyNCT01668017Written as Pimasertib
- Trial of Pimasertib in Hematological MalignanciesTerminatedPhase 2EMD SeronoNCT00957580Written as Pimasertib
- Relative Bioavailability of Pimasertib in Cancer PatientsCompletedPhase 1EMD SeronoNCT01992874Written as Pimasertib Capsule (Part A)
- Oral Bioavailability and Mass Balance Trial With PimasertibCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT01713036Written as Pimasertib
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic CancerCompletedPhase 1/2EMD SeronoNCT01016483Written as Pimasertib
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1EMD SeronoNCT01390818Written as MSC1936369B (pimasertib)
- MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)TerminatedPhase 1/2EMD SeronoNCT01085331Written as Pimasertib
- Oral SAR245408 (XL147) and Oral MSC1936369B in Patients With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1SanofiNCT01357330Written as MSC1936369B
Given beside what is tested · 1 — pimasertib is usual care or a partner of the new treatment
Codes
What other systems call pimasertib · ClinicalTrials.gg INT005662
- UNII (FDA) 6ON9RK82ALPIMASERTIBConfirmed FDA, Wikidata
- Wikidata Q27088393pimasertibConfirmed FDA, Wikidata
- NCI Thesaurus C84864PimasertibOne source FDA
- DrugBank DB14904One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 6ON9RK82AL | PIMASERTIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088393 | pimasertib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C84864 | Pimasertib | One source FDA |
| DrugBank | DB14904 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.